Other oncology — Revenue

Products & Services · Revenue

Eli Lilly Other oncology — Revenue increased by 7.0% to $1.00B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 134.7%, from $427.30M to $1.00B. Over 3 years (FY 2021 to FY 2025), Other oncology — Revenue shows an upward trend with a 122.7% CAGR.

Analysis

StatementSegment
First reportedQ1 2016
Last reportedQ4 2025
Rolls up toTotal Revenue
Metric ID: lly_segment_other_oncology_revenues

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$81.40M$100.30M$77.50M$101.20M$106.80M$102.40M$113.40M$180.20M$260.50M$275.40M$268.50M$299.10M$324.30M$427.30M$788.60M$924.30M$937.40M$1.00B
QoQ Change—+23.2%-22.7%+30.6%+5.5%-4.1%+10.7%+58.9%+44.6%+5.7%-2.5%+11.4%+8.4%+31.8%+84.6%+17.2%+1.4%+7.0%
YoY Change————+31.2%+2.1%+46.3%+78.1%+143.9%+168.9%+49.0%+14.8%+17.8%—+193.7%+209.0%+189.1%+134.7%
Range$77.50M – $1.00B
CAGR+80.6%
Avg YoY Growth+98.4%
Median YoY Growth+78.1%
Current Streak7 quarters growth

Frequently Asked Questions

What is Eli Lilly's other oncology — revenue?
Eli Lilly (LLY) reported other oncology — revenue of $1.00B in Q4 2025.
How has Eli Lilly's other oncology — revenue changed year-over-year?
Eli Lilly's other oncology — revenue increased by 134.7% year-over-year, from $427.30M to $1.00B.
What is the long-term trend for Eli Lilly's other oncology — revenue?
Over 3 years (2021 to 2025), Eli Lilly's other oncology — revenue has grown at a 122.7% compound annual growth rate (CAGR), from $330.80M to $3.65B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.

Eli Lilly (LLY) Other oncology — Revenue — Quarterly & Annual | OpenCapital